Short Report

Journal of Inherited Metabolic Disease

, Volume 31, Supplement 2, pp 329-332

First online:

d-Ribose therapy in four Polish patients with adenylosuccinate lyase deficiency: Absence of positive effect

  • A. JureckaAffiliated withDepartment of Metabolic Diseases, Endocrinology and Diabetology, The Children’s Memorial Health Institute Email author 
  • , A. Tylki-SzymanskaAffiliated withDepartment of Metabolic Diseases, Endocrinology and Diabetology, The Children’s Memorial Health Institute
  • , M. ZikanovaAffiliated withInstitute for Inherited Metabolic Disorders, Charles University, 1st Faculty of Medicine
  • , J. KrijtAffiliated withInstitute for Inherited Metabolic Disorders, Charles University, 1st Faculty of Medicine
  • , S. KmochAffiliated withInstitute for Inherited Metabolic Disorders, Charles University, 1st Faculty of Medicine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

Deficiency of adenylosuccinate lyase (ADSL) (OMIM 103050) is an autosomal recessive disorder of the purine de novo synthesis pathway and purine nucleotide cycle, diagnosed so far in approximately 50 patients. The clinical presentation is characterized by severe neurological involvement including hypotonia, seizures, developmental delay and autistic features. Epilepsy in ADSL deficiency is frequent and occurs in approximately two-thirds of patients, beginning either early in the neonatal period or after the first year of life. At present there is no treatment of proven clinical efficacy. Despite of the increasing number of ADSL-deficient patients reported, there are only a few communications of therapeutic considerations or efforts. Among them only two showed some beneficial effects in ADSL-deficient patients. d-Ribose, a simple and relatively cheap therapy, has been associated with improvement of behaviour and progressive reduction of the seizure frequency in one 13-year-old patient with ADSL deficiency. In this study we have re-examined d-ribose treatment in four ADSL-deficient patients. Assessments consisted of biochemical markers and neurological outcome. The 12-month trial of d-ribose failed to show any clinical benefit in ADSL patients with both milder and severe phenotype. d-Ribose administration was accompanied by neither reduction in seizure frequency nor growth enhancement. Additionally, patients with milder type II presented the first seizure after 4 and 8 months of the d-ribose treatment. Therefore, we could not confirm a positive effect of d-ribose as previously reported.